Results 121 to 130 of about 228,991 (253)

Complement inhibition by a unique cluster of immunomodulatory outer surface proteins of Borrelia recurrentis. [PDF]

Nat Commun
Röttgerding F, Reyer F, Gerlach E, Amborn M, Duschek N, Schultze TG, Fingerle V, Roome CM, Stumpf M, Becker K, Rahlfs S, Przyborski JM, Kraiczy P, Fritz-Wolf K.   +13 more
europepmc   +1 more source

Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina, Anna Marcé‐Grau, Barbara Masotto, Marta Codina, Lamia BenJemaa, Yasmina Elaribi, Mónica Martinez‐Gallo, Roger Colobran, Angel Sanchez‐Montañez, Irene Valenzuela, Yoshiko Murakami, Alfons Macaya   +11 more
wiley   +1 more source

Complement Inhibition Therapy in Myasthenic Crisis-A Multicentre Retrospective Analysis of 17 Cases From Germany. [PDF]

Eur J Neurol
Gerischer L, Stein M, Schneider A, Tangen H, Loris J, Glaubitz S, Zschüntzsch J, Oy UH, Schubert C, Heesen C, Schlag M, Hagenacker T, Oeztuerk M, Ruck T, Doksani P, Dusemund C, Herdick M, Herzig-Nichtweiß J, Mergenthaler P, Stascheit F, Suboh A, Schwarz L, Hoffmann S, Meisel A, Lehnerer S.   +24 more
europepmc   +1 more source

Efficacy of Intermittent Theta‐Burst Stimulation for Prolonged Disorders of Consciousness: A Prospective, Randomized, Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Emerging evidence suggests that low‐frequency neural oscillations are dynamically regulated by consciousness levels, with the recovery of low cortical activity potentially serving as a neurophysiological substrate for conscious emergence. Targeted enhancement of these low‐frequency rhythms in patients with disorders of consciousness
Chuan Xu, Jun Hu, Qianqian Wu, Min Wu, Yamei Yu, Hangcheng Li, Jian Gao, Jingqi Li, Nai Ding, Jie Yu, Benyan Luo   +10 more
wiley   +1 more source

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series. [PDF]

Neurol Neuroimmunol Neuroinflamm
Rommer PS, Jiang W, Nolte JP, Mikami T, De Seze J, Sánchez P, Harel A, Alkabie S, Kaneko K, Bilodeau PA, Misu T, Kremer L, Bigaut K, Leypoldt F, Aktas O, Ringelstein M, Siffrin V, Zhang LJ, Cong H, Lowe M, Barreras P, Chen H, Piquet AL, Sotirchos ES, Kammeyer R, Zook J, Bennett JL, Berger T, Fujihara K, Levy M, Shi FD, Paul F.   +31 more
europepmc   +1 more source

Complement Inhibition in Kidney Transplantation: Where Are We Now? [PDF]

BioDrugs, 2023
Vonbrunn E, Büttner-Herold M, Amann K, Daniel C.   +3 more
europepmc   +1 more source

Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock, Jin Nakahara, Becky Parks, Kerstin Allen, Sami Fam   +4 more
wiley   +1 more source

Biodegradable Polyglycerols Combining Antioxidant Activity and Sulfation-Induced Complement Inhibition. [PDF]

Biomacromolecules
Koeppe H, Horn D, Dernedde J, Haag R.
europepmc   +1 more source

Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. [PDF]

Front Immunol, 2023
Golomingi M, Kohler J, Lamers C, Pouw RB, Ricklin D, Dobó J, Gál P, Pál G, Kiss B, Dopler A, Schmidt CQ, Hardy ET, Lam W, Schroeder V.   +13 more
europepmc   +1 more source

ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Kaixin Yan, Yan Jiang, Yuxuan Yong, Tianshuo Zhang, Niannian Zhang, Qianqian Zeng, Xue Gong, Li Meng, Fangfang Bi, Yongmin Liu   +9 more
wiley   +1 more source